DeepMed Research

Timolol

Generic Name: Timolol

Brand Names: Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₄N_₄O_₃S

CAS Number: 26839-75-8

Unique Ingredient Identifier: 5JKY92S7BR

Background: Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

Indication: Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.

Associated Conditions: Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)

Clinical Trials

Adherence Assessment With Travalert Dosing Aid

Phase 4

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)
Drug: Travoprost 0.004% eye drops
Device: Travalert Dosing Aid
Drug: Timolol 0.05% eye drops

First Posted Date: 2007-07-30

Last Posted Date: 2012-07-12

Lead Sponsor: Alcon Research

Target Recruit Count: 102

Registration Number: NCT00508469

Locations: 🇪🇸
Zaragoza, Zaragoza, Spain

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/timolol 0.5% ophthalmic solution
Drug: Travoprost ophthalmic solution, 0.004%
Drug: Timolol maleate ophthalmic solution, 0.5%

First Posted Date: 2007-04-25

Last Posted Date: 2014-07-24

Lead Sponsor: Alcon Research

Target Recruit Count: 81

Registration Number: NCT00465803

Locations: 🇺🇸
Seattle, Seattle, Washington, United States

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Phase 3

Completed

Conditions: Glaucoma

Interventions: Drug: dorzolamide hydrochloride (+) timolol maleate

First Posted Date: 2007-03-21

Last Posted Date: 2017-06-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 474

Registration Number: NCT00449956

Visual Function Changes After Intraocular Pressure Reduction

Not Applicable

Completed

Conditions: Glaucoma

First Posted Date: 2007-02-14

Last Posted Date: 2007-02-19

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 54

Registration Number: NCT00435058

Beta Blocker for Chronic Wound Healing

Phase 2

Terminated

Conditions: Burns
Ulcer

Interventions: Other: Placebo
Drug: Timoptic

First Posted Date: 2006-08-25

Last Posted Date: 2015-04-07

Lead Sponsor: University of California, Davis

Target Recruit Count: 40

Registration Number: NCT00368602

Locations: 🇺🇸
VA Medical Center, Mather, California, United States

24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients

Phase 4

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

First Posted Date: 2006-05-29

Last Posted Date: 2014-05-12

Lead Sponsor: Aristotle University Of Thessaloniki

Target Recruit Count: 30

Registration Number: NCT00330577

Locations: 🇬🇷
Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

Phase 2

Completed

Conditions: Glaucoma, Open Angle

First Posted Date: 2006-04-25

Last Posted Date: 2006-04-25

Lead Sponsor: Chicago Center for Vision Research

Target Recruit Count: 160

Registration Number: NCT00317577

Locations: 🇺🇸
Little Rock Eye Clinic, Little Rock, Arkansas, United States
🇺🇸
Bascom Palmer Eye Institute, Palm Beach Gardens, Florida, United States
🇺🇸
University Eye Specialists, Chicago, Illinois, United States

and more 9 locations

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Timolol 5 mg/ml eye drops, solution
Drug: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Drug: Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension

First Posted Date: 2006-04-13

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 523

Registration Number: NCT00314158

Locations: 🇺🇸
United States Investigative Sites, Fort Worth, Texas, United States

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Drug: Timolol 0.5% Ophthalmic Solution
Other: Timolol Vehicle

First Posted Date: 2006-02-20

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 173

Registration Number: NCT00293800

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Drug: Timolol Maleate Ophthalmic Solution 0.5%
Other: Timolol Vehicle

First Posted Date: 2006-02-20

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 156

Registration Number: NCT00293787

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy